- Home
- IMCC vs MYNZ Comparison
IMCC vs MYNZ Comparison
Compare IMCC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- MYNZ
- Stock Information
- Founded
- IMCC 1980
- MYNZ 2021
- Country
- IMCC Israel
- MYNZ Germany
- Employees
- IMCC N/A
- MYNZ N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- MYNZ Health Care
- Exchange
- IMCC Nasdaq
- MYNZ Nasdaq
- Market Cap
- IMCC 12.2M
- MYNZ 7.9M
- IPO Year
- IMCC N/A
- MYNZ 2021
- Fundamental
- Price
- IMCC $1.99
- MYNZ $1.58
- Analyst Decision
- IMCC
- MYNZ Buy
- Analyst Count
- IMCC 0
- MYNZ 2
- Target Price
- IMCC N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- IMCC 70.0K
- MYNZ 74.3K
- Earning Date
- IMCC 11-13-2025
- MYNZ 10-21-2025
- Dividend Yield
- IMCC N/A
- MYNZ N/A
- EPS Growth
- IMCC N/A
- MYNZ N/A
- EPS
- IMCC N/A
- MYNZ N/A
- Revenue
- IMCC $38,430,631.00
- MYNZ $893,991.00
- Revenue This Year
- IMCC $47.12
- MYNZ $26.06
- Revenue Next Year
- IMCC $12.83
- MYNZ $4.97
- P/E Ratio
- IMCC N/A
- MYNZ N/A
- Revenue Growth
- IMCC 5.08
- MYNZ N/A
- 52 Week Low
- IMCC $1.29
- MYNZ $1.30
- 52 Week High
- IMCC $7.12
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- IMCC 41.14
- MYNZ 42.60
- Support Level
- IMCC $1.74
- MYNZ $1.58
- Resistance Level
- IMCC $2.03
- MYNZ $1.79
- Average True Range (ATR)
- IMCC 0.25
- MYNZ 0.09
- MACD
- IMCC 0.00
- MYNZ -0.01
- Stochastic Oscillator
- IMCC 45.94
- MYNZ 10.63
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.